Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs

Journal of Thoracic and Cardiovascular Surgery

Volumn 127, Issue 5, 2004, Pages 1285-1292

  Thelitz, Stephan ^a   Bekker, Janine M ^b   Ovadia, Boaz ^b   Stuart, Regan B ^b   Johengen, Michael J ^b   Black, Stephen M ^c   Fineman, Jeffrey R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SOLUBLE GUANYLATE CYCLASE; BETA SOLUBLE GUANYLATE CYCLASE; CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SOLUBLE GUANYLATE CYCLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTIFICIAL VENTILATION; BRONCHUS MUSCLE; CONTROLLED STUDY; DRUG WITHDRAWAL; ENZYME ACTIVITY; LAMB; LUNG BIOPSY; LUNG VASOCONSTRICTION; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REBOUND; SMOOTH MUSCLE FIBER; VASODILATATION; WESTERN BLOTTING;

EID: 2342428465     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2003.07.024     Document Type: Article

References (30)

1. Atz AM, Wessel DL. Inhaled nitric oxide in the neonate with cardiac disease. Semin Perinatol. 1997;21:441-55.
2. Canadian Inhaled Nitric Oxide Study Group and the NICHD Neonatal Research Network. The neonatal inhaled nitric oxide study in the term and near-term infant with hypoxic respiratory failure: a multicenter randomized trial. N Engl J Med. 1997;336:597-604.
3. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med. 2000;342:469-74.
4. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-405.
5. Ignarro LJ, Ross G, Tillisch J. Pharmacology of endothelium-derived nitric oxide and nitrovasodilators. West J Med. 1991;154:51-62.
6. Christou H, Adatia I, Van Marter LJ, Kane JW, Thompson JE, Stark AR, et al. Effect of inhaled nitric oxide on endothelin-1 and cyclic guanosine 5′-monophosphate plasma concentrations in newborn infants with persistent pulmonary hypertension. J Pediatr. 1997;130: 603-11.
7. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995;75:725-48.
8. Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, Bloch KD. Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res. 1998;43:163-8.
9. Day RW, Allen EM, Witte MK. A randomized, controlled study of the 1-hour and 24-hour effects of inhaled nitric oxide therapy in children with acute hypoxemic respiratory failure. Chest. 1997;112:1324-31.
10. Dellinger RP, Zimmerman JL, Taylor RW, Straube RC, Hauser DL, Criner GJ, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 1998;26: 15-23.
11. Atz A, Adatia I, Wessel D. Rebound pulmonary hypertension after inhalation of nitric oxide. Ann Thorac Surg. 1996;62:1759-64.
12. Lavoie A, Hall JB, Olson DM, Wylam ME. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med. 1996;153:1985-7.
13. Black SM, Heidersbach RS, McMullan DM, Bekker JM, Johengen MJ, Fineman JR. Inhaled nitric oxide inhibits nitric oxide synthase activity in lambs. A potential mechanism for rebound pulmonary hypertension. Am J Physiol. 1999;277:H1849-56.
14. Sheehy AM, Burson MA, Black SM. Nitric oxide exposure inhibits endothelial NOS activity but not gene expression: a role for superoxide. Am J Physiol. 1998;274:L833-41.
15. Buga GM, Griscavage JM, Rogers NE, Ignarro LJ. Negative feedback regulation of endothelial cell function by nitric oxide. Circ Res. 1993;73:808-12.
16. Ujiiie K, Hogarth L, Danziger R, Drewett JG, Yuen P, Pang IH, et al. Homologous and heterologous desensitization of a guanylate cyclase-linked nitric oxide receptor in cultured rat medullary interstitial cells. J Pharmacol Exp Ther. 1994;270:761-7.
17. Filippov G, Bloch DB, Bloch KD. Nitric oxide decreases stability of mRNAs encoding soluble guanylate cyclase subunits in rat pulmonary artery smooth muscle cells. J Clin Invest. 1997;100:942-8.
18. Black SM, Sanchez LS, Bekker JM, Steinhorn RH, Fineman JR. Increased expression of soluble guanylate cyclase and phosphodiesterase type 5 in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol. 2001;281:L1051-7.
19. Kamisaki Y, Saheki S, Nakane M, Palmieri JA, Kuno T, Chang BY, et al. Soluble guanylate cyclase from rat lung exists as a heterodimer. J Biol Chem. 1986;261:7236-41.
20. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation. 1993;87:440-6.
21. Steinhorn RH, Russell JA, Morin FC III. Disruption of cGMP production in pulmonary arteries isolated from fetal lambs with pulmonary hypertension. Am J Physiol. 1995;268:H1483-9.
22. Tzao C, Nickerson PA, Russell JA, Gugino SF, Steinhorn RH. Pulmonary hypertension alters soluble guanylate cyclase activity and expression in pulmonary arteries isolated from fetal lambs. Pediatr Pulmonol. 2001;31:97-105.
23. Ruetten H, Zabel U, Linz W, Schmidt H. Downregulation of soluble guanylate cyclase in young and aging spontaneously hypertensive rats. Circ Res. 1999;85:534-41.
24. Lewko B, Wendt U, Szczepanska-Konkel M, Stepinski J, Drewnowska K, Angielski S. Inhibition of endogenous nitric oxide synthesis activates particulate guanylyl cyclase in the rat renal glomeruli. Kidney Int. 1997;52:654-9.
25. Sanchez LS, Bloch KD, Morin FC, Steinhorn RH. Phosphodiesterase 5 (PDE5) enzyme activity and gene expression are altered in newborn lambs with persistent pulmonary hypertension [abstract]. Pediatr Res. 1997;41:267A.
26. McMullan DM, Bekker JM, Johengen MJ, Hendricks-Munoz K, Gerrets R, Black SM, et al. Inhaled nitric oxide-induced rebound pulmonary hypertension: a role for endothelin-1. Am J Physiol. 2001;280: H777-85.
27. Wedgwood S, McMullan DM, Bekker JM, Fineman JR, Black SM. A role for ET-1 induced superoxide production in rebound pulmonary hypertension associated with inhaled NO therapy. Circ Res. 2001;89: 357-64.
28. Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc Res. 2001;51:429-41.
29. Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J Thorac Cardiovasc Surg. 2002;124:628-9.
30. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology. 1999;91:307-10.